Coeptis Therapeutics (ZSQR) Competitors

$8.98 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

ZSQR vs. FATE, VYGR, WHWK, UNCY, and IPHA

Should you buy Coeptis Therapeutics stock or one of its competitors? MarketBeat compares Coeptis Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coeptis Therapeutics include Fate Therapeutics (FATE), Voyager Therapeutics (VYGR), Whitehawk Therapeutics (WHWK), Unicycive Therapeutics (UNCY), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.

How does Coeptis Therapeutics compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Coeptis Therapeutics has a net margin of -810.04% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Coeptis Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	39.44	-$136.32M	-$1.09	N/A
Coeptis Therapeutics	$1.36M	339.59	-$11.92M	-$2.52	N/A

Fate Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

Fate Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 127.78%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Fate Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Fate Therapeutics had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Coeptis Therapeutics. Fate Therapeutics' average media sentiment score of 0.47 beat Coeptis Therapeutics' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Fate Therapeutics beats Coeptis Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Voyager Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Voyager Therapeutics has a net margin of -319.61% compared to Coeptis Therapeutics' net margin of -810.04%. Voyager Therapeutics' return on equity of -55.97% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 334.21%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 1 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.76 beat Coeptis Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coeptis Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	339.59	-$11.92M	-$2.52	N/A
Voyager Therapeutics	$40.37M	5.69	-$119.72M	-$1.97	N/A

Coeptis Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summary

Voyager Therapeutics beats Coeptis Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Coeptis Therapeutics has higher revenue and earnings than Whitehawk Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	N/A	N/A	-$20.60M	-$1.68	N/A
Coeptis Therapeutics	$1.36M	339.59	-$11.92M	-$2.52	N/A

Whitehawk Therapeutics has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Whitehawk Therapeutics' return on equity of -79.63% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Whitehawk Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 2 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.00 beat Whitehawk Therapeutics' score of -0.25 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Whitehawk Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 63.33%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Whitehawk Therapeutics beats Coeptis Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Unicycive Therapeutics has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Coeptis Therapeutics' return on equity of -92.29% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Unicycive Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 2 mentions for Coeptis Therapeutics. Unicycive Therapeutics' average media sentiment score of 1.16 beat Coeptis Therapeutics' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coeptis Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$2.21	N/A
Coeptis Therapeutics	$1.36M	339.59	-$11.92M	-$2.52	N/A

Unicycive Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 197.03%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Unicycive Therapeutics beats Coeptis Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Innate Pharma has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

Innate Pharma has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Innate Pharma's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Coeptis Therapeutics has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.87	-$55.64M	N/A	N/A
Coeptis Therapeutics	$1.36M	339.59	-$11.92M	-$2.52	N/A

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innate Pharma currently has a consensus target price of $5.00, indicating a potential upside of 173.22%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Innate Pharma beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$461.84M	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-3.56	18.91	21.01	25.66
Price / Sales	339.59	329.35	615.84	111.99
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	26.41	7.09	10.37	7.14
Net Income	-$11.92M	$24.45M	$3.57B	$335.98M
7 Day Performance	-4.26%	5.45%	6.01%	3.56%
1 Month Performance	-45.24%	2.43%	3.52%	2.54%
1 Year Performance	-13.74%	62.98%	34.13%	35.05%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZSQR Coeptis Therapeutics	0.0455 of 5 stars	$8.98 flat	N/A	-13.7%	$461.84M	$1.36M	N/A	2	Gap Down
FATE Fate Therapeutics	3.1159 of 5 stars	$1.84 -2.6%	$5.13 +178.5%	+94.0%	$214.47M	$6.32M	N/A	550
VYGR Voyager Therapeutics	2.9259 of 5 stars	$3.50 +0.6%	$16.50 +371.4%	+30.1%	$211.47M	$36.49M	N/A	100
WHWK Whitehawk Therapeutics	2.9347 of 5 stars	$4.22 +3.7%	$7.33 +73.8%	N/A	$208.68M	$7.14M	N/A	21
UNCY Unicycive Therapeutics	3.345 of 5 stars	$7.74 +0.1%	$24.00 +210.1%	+46.1%	$206.66M	$680K	N/A	9	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. FATE, VYGR, WHWK, UNCY, and IPHA

How does Coeptis Therapeutics compare to Fate Therapeutics?

Summary

How does Coeptis Therapeutics compare to Voyager Therapeutics?

Summary

How does Coeptis Therapeutics compare to Whitehawk Therapeutics?

Summary

How does Coeptis Therapeutics compare to Unicycive Therapeutics?

Summary

How does Coeptis Therapeutics compare to Innate Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. FATE, VYGR, WHWK, UNCY, and IPHA

How does Coeptis Therapeutics compare to Fate Therapeutics?

Is FATE or ZSQR more profitable?

Which has better valuation and earnings, FATE or ZSQR?

Which has more risk & volatility, FATE or ZSQR?

Do analysts recommend FATE or ZSQR?

Does the media favor FATE or ZSQR?

Do insiders & institutionals hold more shares of FATE or ZSQR?

Summary

How does Coeptis Therapeutics compare to Voyager Therapeutics?

Is ZSQR or VYGR more profitable?

Do insiders and institutionals have more ownership in ZSQR or VYGR?

Do analysts prefer ZSQR or VYGR?

Does the media prefer ZSQR or VYGR?

Which has preferable valuation & earnings, ZSQR or VYGR?

Which has more risk & volatility, ZSQR or VYGR?

Summary

How does Coeptis Therapeutics compare to Whitehawk Therapeutics?

Do institutionals & insiders believe in WHWK or ZSQR?

Which has preferable valuation & earnings, WHWK or ZSQR?

Is WHWK or ZSQR more profitable?

Which has more volatility and risk, WHWK or ZSQR?

Does the media refer more to WHWK or ZSQR?

Do analysts recommend WHWK or ZSQR?

Summary

How does Coeptis Therapeutics compare to Unicycive Therapeutics?

Is UNCY or ZSQR more profitable?

Which has more volatility and risk, UNCY or ZSQR?

Do insiders and institutionals have more ownership in UNCY or ZSQR?

Does the media refer more to UNCY or ZSQR?

Which has stronger earnings and valuation, UNCY or ZSQR?

Do analysts rate UNCY or ZSQR?

Summary

How does Coeptis Therapeutics compare to Innate Pharma?

Which has more volatility and risk, IPHA or ZSQR?

Is IPHA or ZSQR more profitable?

Which has stronger valuation & earnings, IPHA or ZSQR?

Does the media favor IPHA or ZSQR?

Do analysts recommend IPHA or ZSQR?

Do institutionals & insiders believe in IPHA or ZSQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools